1-20 of 29
Adi Diab
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT176: OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy induced deepening and durable responses without interleukin 2 (IL2) in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma

Rodabe N. Amaria, Jennifer L. McQuade, Michael A. Davies, Isabella C. Glitza Oliva, Steffy Jose, Erik N. Cressman, Ashlynd L. Clausell, Roland Bassett, Sapna Patel, Adi Diab, Hussein A. Tawbi, Michael K. Wong, Alexandra P. Ikeguchi, Madan Jagasia, Giridharan Ramsingh, Prakash Prabhakar, Raina Duan, Parameswaran Hari
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT176.
https://doi.org/10.1158/1538-7445.AM2024-CT176
Published: 05 April 2024
View article titled, Abstract CT176: OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy induced deepening and durable responses without interleukin 2 (IL2) in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma
Journal Articles

Abstract 3605: Phase II study of pembrolizumab in conjunction with lymphodepletion, TIL ACT, and high- or low-dose IL-2 in patients with metastatic melanoma

Merve Hasanov, Simin Kiany, Marie-Andrée Forget, Roland L. Bassett, Michael A. Davies, Adi Diab, Jeffrey E. Gershenwald, Isabella C. Glitza, Jeffrey E. Lee, Anthony Lucci, Jennifer L. McQuade, Sapna P. Patel, Merrick I. Ross, Hussein A. Tawbi, Jennifer Wargo, Michael K. Wong, Chantale Bernatchez, Patrick Hwu, Cara Haymaker, Rodabe N. Amaria
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3605.
https://doi.org/10.1158/1538-7445.AM2024-3605
Published: 22 March 2024
View article titled, Abstract 3605: Phase II study of pembrolizumab in conjunction with lymphodepletion, TIL ACT, and high- or low-dose IL-2 in patients with metastatic melanoma
Journal Articles

Abstract 1485: Elucidating the role of VGLL1 in pancreatic cancer tumorigenesis

Heather M. Sonnemann, Barbara Pazdrak, Barbara Nassif, Yimo Sun, Lama Elzohary, Amjad Talukder, Arjun Katailiha, Salah-Eddine Bentebibel, Adi Diab, Gregory Lizee
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1485.
https://doi.org/10.1158/1538-7445.AM2023-1485
Published: 04 April 2023
View article titled, Abstract 1485: Elucidating the role of VGLL1 in pancreatic cancer tumorigenesis
Journal Articles

Abstract 5079: Intratumoral CD40 agonist enhances the antitumor effect of anti-PD1 immunotherapy by activation of antigen-presenting cells and selective expansion of effector CD8+ T cells

Barbara Pazdrak, Heather M. Sonnemann, Salah-Eddine Bentebibel, Barbara M. Nassif, Greg Lizee, Adi Diab
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5079.
https://doi.org/10.1158/1538-7445.AM2023-5079
Published: 04 April 2023
View article titled, Abstract 5079: Intratumoral CD40 agonist enhances the antitumor effect of anti-PD1 immunotherapy by activation of antigen-presenting cells and selective expansion of effector CD8+ T cells
Journal Articles

Abstract CT039: Intratumoral CD40 agonist sotigalimab with pembrolizumab induces broad innate and adaptive immune activation in local and distant tumors in metastatic melanoma

Salah-Eddine Bentebibel, Daniel Johnson, Rodabe Amariae, Daniel McGrail, Srisuda Lecagoonporn, Cara Haymaker, Dzifa Duose, Khalida Wani, Houssein Safa, Isabella Claudia Glitza, Sapna Pradyuman Patel, Michael K. Wong, Hussein Tawbi, Jared Burks, Xiaodong Yang, Patrick Hwu, Cassian Yee, Michael A. Davies, Ravi Murthy, Chantale Bernatchez, Suhendan Ekmekcioglu, Adi Diab, Gregory Lizée
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT039.
https://doi.org/10.1158/1538-7445.AM2022-CT039
Published: 15 June 2022
View article titled, Abstract CT039: Intratumoral CD40 agonist sotigalimab with pembrolizumab induces broad innate and adaptive immune activation in local and distant tumors in metastatic melanoma
Journal Articles

Abstract 4177: Th17 inhibition with interleukin 6 blockade decouples immunotoxicity from tumor immunity

Daniel H. Johnson, Yared Hailemichael, Salah-Eddine Bentebibel, Noha Abdel-Wahab, Sungnam Cho, Wai C. Foo, Khalida Wani, Stephanie S. Watowich, Suhendan Ekmekcioglu, Adi Diab
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4177.
https://doi.org/10.1158/1538-7445.AM2022-4177
Published: 15 June 2022
View article titled, Abstract 4177: Th17 inhibition with interleukin 6 blockade decouples immunotoxicity from tumor immunity
Journal Articles

Abstract 5545: Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration

Yifan Zhou, Yusra B. Medik, Bhakti Patel, Daniel B. Zamler, Sijie Chen, Thomas Chapman, Sarah Schneider, Rachel L. Babcock, Taylor T. Chrisikos, Laura M. Kahn, Allison M. Dyevoich, Elizabeth M. Park, Alexandria P. Cogdill, Daniel H. Johnson, Sarah B. Johnson, Khalida M. Wani, Debora A. Ledesma, Courtney W. Hudgens, Jingjing Wang, Md Abdul Wadud Khan, Aron Y. Joon, Weiyi Peng, Haiyan S. Li, Reetakshi Arora, Ximing Tang, Maria Gabriela Raso, Xuegong Zhang, Wai Chin Foo, Michael T. Tetzlaff, Gretchen E. Diehl, Karen Clise-Dwyer, Elizabeth M. Whitley, Matthew M. Gubin, James P. Allison, Patrick Hwu, Nadim J. Ajami, Adi Diab, Jennifer A. Wargo, Stephanie S. Watowich
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5545.
https://doi.org/10.1158/1538-7445.AM2022-5545
Published: 15 June 2022
View article titled, Abstract 5545: Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
Journal Articles

Abstract A09: Characteristics of uveal melanoma patients with central nervous system metastases

Sapna P. Patel, Patrick Hwu, Michael Davies, Michael Wong, Hussein Tawbi, Rodabe Amaria, Adi Diab, Dan Gombos, Isabella C. Glitza
Journal: Cancer Research
Cancer Res (2020) 80 (19_Supplement): A09.
https://doi.org/10.1158/1538-7445.MEL2019-A09
Published: 02 October 2020
View article titled, Abstract A09: Characteristics of uveal melanoma patients with central nervous system metastases
Journal Articles

Abstract A13: Clinical characteristics of responders to nivolumab plus ipilimumab (Nivo/Ipi) in metastatic uveal melanoma

Michael Paul Shephard, Maura Glover, Gener Balmes, Suzanne Cain, Anna Vardeleon, Rosalind Mouton, Liberty Posada, Rinata Simien, Patrick Hwu, Michael Davies, Cassian Yee, Michael Wong, Hussein Tawbi, Scott Woodman, Rodabe Amaria, Adi Diab, Isabella Glitza, Wen-Jen Hwu, Sapna Patel
Journal: Cancer Research
Cancer Res (2020) 80 (19_Supplement): A13.
https://doi.org/10.1158/1538-7445.MEL2019-A13
Published: 02 October 2020
View article titled, Abstract A13: Clinical characteristics of responders to nivolumab plus ipilimumab (Nivo/Ipi) in metastatic uveal melanoma
Journal Articles

Abstract CT134: Tilsotolimod engages the TLR9 pathway to promote antigen presentation and Type-I IFN signaling in solid tumors

Hani M. Babiker, Vivek Subbiah, Asim Ali, Alain Algazi, Jacob Schachter, Michal Lotem, Corinne Maurice-Dror, Daniel Hendler, Shah Rahimian, Hans Minderman, Cara Haymaker, Chantale Bernatchez, Ravi Murthy, Rolf Hultsch, Nadia Caplan, Gregory Woodhead, Charles Hennemeyer, Sri Chunduru, Peter Anderson, Adi Diab, Erkut Borazanci, Igor Puzanov
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT134.
https://doi.org/10.1158/1538-7445.AM2020-CT134
Published: 15 August 2020
View article titled, Abstract CT134: Tilsotolimod engages the TLR9 pathway to promote antigen presentation and Type-I IFN signaling in solid tumors
Journal Articles

Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors

Christine N. Spencer, Vancheswaran Gopalakrishnan, Jennifer McQuade, Miles C. Andrews, Beth Helmink, M.A. Wadud Khan, Elizabeth Sirmans, Lauren Haydu, Alexandria Cogdill, Elizabeth Burton, Rodabe Amaria, Sapna Patel, Isabella Glitza, MIchael Davies, Eliza Posada, Wen-Jen Hwu, Adi Diab, Kelly Nelson, Hussein Tawbi, Michael Wong, Robert R. Jenq, Lorenzo Cohen, Carrie Daniel-MacDougall, Jennifer A. Wargo
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2838.
https://doi.org/10.1158/1538-7445.AM2019-2838
Published: 01 July 2019
View article titled, Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors
Journal Articles

Abstract 1493: Therapeutic efficacy and tolerability of combined immune checkpoint blockade in metastatic melanoma patients is influenced by the gut microbiome

Vancheswaran Gopalakrishnan, Miles Andrews, Wei-Shen Chen, Christine Spencer, Luis Vence, Alexandre Reuben, Zachary A. Cooper, Peter A. Prieto, Michael T. Tetzlaff, MA Abdul Wadud Khan, Alexander Lazar, Courtney W. Hudgens, Lauren E. Haydu, Hussein A. Tawbi, Patrick Hwu, Wen-Jen Hwu, Rodabe N. Amaria, Elizabeth M. Burton, Scottt E. Woodman, Adi Diab, Sapna P. Patel, Isabella C. Glitza, Jianhua Zhang, Joseph Petrosino, Robert R. Jenq, Michael A. Davies, Jeffrey E. Gershenwald, Padmanee Sharma, James P. Allison, Andrew Futreal, Jennifer A. Wargo
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1493.
https://doi.org/10.1158/1538-7445.AM2019-1493
Published: 01 July 2019
View article titled, Abstract 1493: Therapeutic efficacy and tolerability of combined immune checkpoint blockade in metastatic melanoma patients is influenced by the gut microbiome
Journal Articles

Abstract 941: B cells are required to generate optimal antitumor immunity in response to PD-1 blockade treatment

Shubhra Singh, Karishma Bavisi, Jason Roszik, Adi Diab, Richard E. Davis, Patrick Hwu, Willem W. Overwijk, Manisha Singh
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 941.
https://doi.org/10.1158/1538-7445.AM2019-941
Published: 01 July 2019
View article titled, Abstract 941: B cells are required to generate optimal antitumor immunity in response to PD-1 blockade treatment
Journal Articles

Abstract 4062: Activation of innate and adaptive immunity using intratumoral tilsotolimod (IMO-2125) as monotherapy in patients with refractory solid tumors: a phase Ib study (ILLUMINATE-101)

Hani M. Babiker, Vivek Subbiah, Orla Maguire, Shah Rahimian, Hans Minderman, Cara L. Haymaker, Chantale Bernatchez, Erkut Borazanci, James Geib, Srinivas K. Chunduru, Peter M. Anderson, Igor Puzanov, Adi Diab
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4062.
https://doi.org/10.1158/1538-7445.AM2019-4062
Published: 01 July 2019
View article titled, Abstract 4062: Activation of innate and adaptive immunity using intratumoral tilsotolimod (IMO-2125) as monotherapy in patients with refractory solid tumors: a phase Ib study (ILLUMINATE-101)
Journal Articles

Abstract 3640: Treatment strategies using anti-PD1/PD-L1 (anti-PD) and BRAF/MEK inhibitor (BRAFi) therapy: a retrospective study comparing sequential vs. concurrent administration in BRAF-mutated metastatic melanoma (BMMM)

Rodabe N. Amaria, Van A. Trinh, Jun Gu, Susan McIntyre, Carlos Torres Cabala, Rinata Simien, Adi Diab, Hussein A. Tawbi, Michael A. Davies, Michael K. Wong, Patrick Hwu, Isabella C. Glitza, Sapna P. Patel, Wen Jen Hwu
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3640.
https://doi.org/10.1158/1538-7445.AM2018-3640
Published: 01 July 2018
View article titled, Abstract 3640: Treatment strategies using anti-PD1/PD-L1 (anti-PD) and BRAF/MEK inhibitor (BRAFi) therapy: a retrospective study comparing sequential vs. concurrent administration in BRAF-mutated metastatic melanoma (BMMM)
Journal Articles

Abstract CT177: Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study

Aung Naing, John D. Powderly, Gerald Falchook, Benjamin Creelan, John Nemunaitis, Jose Lutzky, Adi Diab, Judy S. Wang, Naomi Laing, Michelle Niewood, Xiaohua Gong, Gongfu Zhou, Manish Patel
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT177.
https://doi.org/10.1158/1538-7445.AM2018-CT177
Published: 01 July 2018
View article titled, Abstract CT177: Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study
Journal Articles

Abstract CT010: Pharmacodynamic (PD) changes in tumor RNA expression and the peripheral blood T cell receptor (TCR) repertoire in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600)

Adi Diab, Omid Hamid, John A. Thompson, Willeke Ros, Fredericus A. L. M. Eskens, Toshihiko Doi, Siwen Hu-Lieskovan, Hua Long, Tenshang Joh, Shoba Potluri, Xiao Wang, Catherine Fleener, Carrie Turich Taylor, Bishu J. Ganguli, Jeffrey Chou, Anthony B. El-Khoueiry
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT010.
https://doi.org/10.1158/1538-7445.AM2018-CT010
Published: 01 July 2018
View article titled, Abstract CT010: Pharmacodynamic (PD) changes in tumor RNA expression and the peripheral blood T cell receptor (TCR) repertoire in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600)
Journal Articles

Abstract 614: Resiquimod, a Toll-like receptor agonist promotes melanoma regression by enhancing plasmacytoid dendritic cells and T cytotoxic activity as a vaccination adjuvant and by direct tumor application

Jorge A. Borin Scutti, Luis M. Vence, Richard E. Royal, Tara C. Wray, Janice N. Cormier, Jeffrey E. Lee, Anthony Lucci, Jeffrey E. Gershenwald, Merrick I. Ross, Jennifer Wargo, Karen A. Millerchip, Rodabe N. Amaria, Michael A. Davis, Adi Diab, Isabella C. Glitza, Wen Hwu, Sapna Patel, Scott E. Woodman, Willem W. Overwijk, Patrick Hwu
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 614.
https://doi.org/10.1158/1538-7445.AM2018-614
Published: 01 July 2018
View article titled, Abstract 614: Resiquimod, a Toll-like receptor agonist promotes melanoma regression by enhancing plasmacytoid dendritic cells and T cytotoxic activity as a vaccination adjuvant and by direct tumor application
Journal Articles

Abstract 5711: The impact of combination oral azacitidine (CC-486) + pembrolizumab (PEMBRO) on the immune infiltrate in metastatic melanoma (MM)

Emily Z. Keung, Isabella C. Glitza, Elizabeth Burton, Rodabe N. Amaria, Sapna P. Patel, Adi Diab, Cassian Yee, Michael K. Wong, Wen-Jen Hwu, Patrick Hwu, Scott E. Woodman, Michael T. Tetzlaff, Nallely Trujillo-Conley, Denai R. Milton, Michael A. Davies, Kunal Rai, Irina Fernandez, Jorge M. Blando, Luis M. Vence, Padmanee Sharma, James P. Allison, Jennifer A. Wargo, Hussein Tawbi
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 5711.
https://doi.org/10.1158/1538-7445.AM2018-5711
Published: 01 July 2018
View article titled, Abstract 5711: The impact of combination oral azacitidine (CC-486) + pembrolizumab (PEMBRO) on the immune infiltrate in metastatic melanoma (MM)
Journal Articles

Abstract CT156: Novel neoadjuvant targeted therapy trial yields insight into molecular mechanisms of response

Scott E. Woodman, Peter Prieto, Miles C. Andrews, Rodabe N. Amaria, Michael Tetzlaff, Adi Diab, Sapna P. Patel, Hwu Wen-Jen, Isabella Glitza, Hussein Tawbi, Patrick Hwu, Janice Cormier, Anthony Lucci, Richard Royal, Jeffrey Lee, Roland Bassett, Lauren Simpson, Elizabeth Burton, Li Zhao, Elizabeth Grimm, Alexandre Reuben, Christine Spencer, Junna Oba, Merrick Ross, Jeffrey Gershenwald, Michael Davies, Jennifer A. Wargo
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT156.
https://doi.org/10.1158/1538-7445.AM2017-CT156
Published: 01 July 2017
View article titled, Abstract CT156: Novel neoadjuvant targeted therapy trial yields insight into molecular mechanisms of response